Last Price
75.10
Today's Change
+0.48 (0.64%)
Day's Change
72.87 - 75.36
Trading Volume
707,095
Market Cap
14 Billion
Shares Outstanding
192 Million
Avg Volume
2,064,650
Avg Price (50 Days)
71.09
Avg Price (200 Days)
62.67
PE Ratio
834.89
EPS
0.09
Earnings Announcement
11-Feb-2025
Previous Close
74.62
Open
73.02
Day's Range
72.87 - 75.36
Year Range
50.35 - 83.95
Trading Volume
708,109
1 Day Change
0.70%
5 Day Change
-0.75%
1 Month Change
-2.77%
3 Month Change
19.35%
6 Month Change
27.29%
Ytd Change
14.81%
1 Year Change
37.07%
3 Year Change
15.58%
5 Year Change
-20.06%
10 Year Change
-0.08%
Max Change
3907.47%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.